HK1071313A1 - Preventing and/or treating cardiovascular disease and/or associated heart failure - Google Patents
Preventing and/or treating cardiovascular disease and/or associated heart failureInfo
- Publication number
- HK1071313A1 HK1071313A1 HK05104473.3A HK05104473A HK1071313A1 HK 1071313 A1 HK1071313 A1 HK 1071313A1 HK 05104473 A HK05104473 A HK 05104473A HK 1071313 A1 HK1071313 A1 HK 1071313A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- preventing
- patient
- heart failure
- cardiovascular disease
- treating cardiovascular
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000017423 tissue regeneration Effects 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ51772102 | 2002-03-08 | ||
NZ51772502 | 2002-03-11 | ||
US36438202P | 2002-03-12 | 2002-03-12 | |
PCT/NZ2003/000042 WO2003077901A1 (en) | 2002-03-08 | 2003-03-10 | Preventing and/or treating cardiovascular disease and/or associated heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1071313A1 true HK1071313A1 (en) | 2005-07-15 |
Family
ID=28046135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05104473.3A HK1071313A1 (en) | 2002-03-08 | 2005-05-28 | Preventing and/or treating cardiovascular disease and/or associated heart failure |
Country Status (11)
Country | Link |
---|---|
US (4) | US6951890B2 (xx) |
EP (2) | EP1487431B1 (xx) |
JP (1) | JP4860906B2 (xx) |
CN (1) | CN1649577A (xx) |
AT (1) | ATE555782T1 (xx) |
AU (1) | AU2003225442B2 (xx) |
CA (1) | CA2478997C (xx) |
DK (2) | DK1487431T3 (xx) |
ES (1) | ES2386782T3 (xx) |
HK (1) | HK1071313A1 (xx) |
WO (1) | WO2003077901A1 (xx) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018392A1 (en) | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
JP2005504060A (ja) * | 2001-08-24 | 2005-02-10 | メイン・メデイカル・センター・リサーチ・インステイテユート | 銅依存性の非伝統的前炎症性サイトカイン輸送およびそれに関連する方法、組成物およびキット |
US20040038861A1 (en) * | 2001-11-26 | 2004-02-26 | Cooper Garth J. S. | Methods and compositions for normalizing lipid levels in mammalian tissues |
AU2003225442B2 (en) * | 2002-03-08 | 2010-02-04 | Philera New Zealand Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
US20070248689A1 (en) * | 2002-05-24 | 2007-10-25 | Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
CA2490541A1 (en) * | 2002-05-24 | 2003-12-04 | The Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
US20040142393A1 (en) * | 2002-08-01 | 2004-07-22 | Cooper Garth James Smith | Methods of use of compounds with preptin function |
US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
CA3011023A1 (en) * | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Composition comprising triethylenetramine salts for treating tissue damage |
EP1694317A4 (en) * | 2003-12-19 | 2010-05-12 | Protemix Corp Ltd | COPPER ANTAGONIST COMPOUNDS |
CN101247793B (zh) | 2003-12-29 | 2013-04-10 | 哈佛大学校长及研究员协会 | 治疗或预防肥胖和胰岛素抗性病症的组合物 |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US7563460B2 (en) * | 2004-02-26 | 2009-07-21 | Med Five, Inc. | Enteric coated oral pharmaceutical to erode kidney stones |
US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
CA2875095C (en) | 2004-07-19 | 2019-09-03 | Philera New Zealand Limited | Synthesis of triethylenetetramines |
HU227588B1 (hu) * | 2004-12-03 | 2011-09-28 | Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft | Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény |
WO2006104398A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
WO2006104402A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
US7687082B2 (en) * | 2005-04-07 | 2010-03-30 | Astrum Therapeutics Pty. Ltd. | Complementary compositions to reduce blood glucose levels and treat diabetes |
EP1877801A4 (en) * | 2005-04-25 | 2009-03-18 | Protemix Corp Ltd | ANALYSIS AND THERAPY OF COPPER REGULATION |
WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
AU2006312407A1 (en) * | 2005-11-09 | 2007-05-18 | Philera New Zealand Limited | Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits |
EP1993607A4 (en) * | 2006-01-10 | 2012-03-28 | Pipex Inc | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR OBTAINING AND MAINTAINING A TARGETABLE, STABLE COPPER RATE AND PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASES RELATED TO SERIAL COPPER RATE |
KR100821649B1 (ko) | 2006-01-24 | 2008-04-11 | 서울시립대학교 산학협력단 | 클리오퀴놀을 유효성분으로 포함하는 HIF-1α 활성제 |
DE602007006641D1 (de) * | 2006-02-21 | 2010-07-01 | Astrum Therapeutics Pty Ltd | Zusammensetzungen zur verringerung des blutglukosespiegels und zur behandlung von diabetes |
WO2007116243A2 (en) * | 2006-04-10 | 2007-10-18 | Mintails Limited | Method for treating fibromyalgia and related conditions |
CA2654020A1 (en) * | 2006-06-01 | 2007-12-13 | Burton E. Sobel | Methods for inhibiting cardiac pai-1 |
KR100816798B1 (ko) * | 2006-09-08 | 2008-03-25 | (주)팜스웰 | 의약용 트리에틸렌테트라민 이염산염의 제조방법 |
WO2008111956A2 (en) * | 2007-03-09 | 2008-09-18 | Symcopeia Company | Fatty acid oxidation inhibitors treating hyperglycemia and related disorders |
US20100311092A1 (en) * | 2007-11-30 | 2010-12-09 | Kurland Irwin J | Metabolic fuel switching biomarker |
WO2010020959A1 (en) * | 2008-08-21 | 2010-02-25 | University Of Cape Town | Resveratrol-containing composition for treating heart failure |
US20100234906A1 (en) * | 2009-03-16 | 2010-09-16 | Pacesetter, Inc. | System and method for controlling rate-adaptive pacing based on a cardiac force-frequency relation detected by an implantable medical device |
JP5896375B2 (ja) | 2011-09-09 | 2016-03-30 | 池田食研株式会社 | 改変型グルコース脱水素酵素遺伝子 |
WO2014145705A2 (en) | 2013-03-15 | 2014-09-18 | Battelle Memorial Institute | Progression analytics system |
WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
CZ307108B6 (cs) * | 2013-09-06 | 2018-01-17 | Vysoké Učení Technické V Brně | Multifunkční poloprovozní jednotka pro snižování polutantů z odpadního plynu |
EP2845640B1 (en) | 2013-09-06 | 2018-10-24 | Vysoké Ucení Technické V Brne | Multifunction operation unit for reducing pollutant concentration in a waste gas |
MX2017008959A (es) * | 2015-01-07 | 2018-05-17 | Nottingham Univ Hospitals Nhs Trust | Biomarcadores relacionados con la funcion del riñon y metodos que involucran su uso. |
WO2017049529A1 (en) * | 2015-09-24 | 2017-03-30 | Innolife Co., Ltd. | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
US11865162B2 (en) | 2016-07-01 | 2024-01-09 | Marshall University Research Corporation | Compositions and methods for treatment of uremic cardiomyopathy |
CN107811997A (zh) * | 2017-11-10 | 2018-03-20 | 大连医科大学附属第医院 | 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用 |
MA51919A1 (fr) | 2018-05-04 | 2021-11-30 | Orphalan | Forme cristalline du tetrachlorhydrate de triethylenetetramine et utilisation pharmaceutique correspondante |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
EP3947433A4 (en) * | 2019-04-02 | 2022-11-23 | The Regents of The University of Michigan | USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASES |
AU2020294694A1 (en) * | 2019-06-17 | 2022-02-03 | Philera New Zealand Ltd. | Combination treatments for central nervous system disorders |
CN112138024A (zh) * | 2019-06-26 | 2020-12-29 | 里弗斯Pah有限责任公司 | 治疗严重形式的肺动脉高压的方法 |
CN110464717B (zh) * | 2019-09-23 | 2022-02-18 | 张建国 | 一种2,4-二羟基苯甲酸在制备降低血糖的药物的应用 |
GB2612210A (en) * | 2020-06-24 | 2023-04-26 | Reverspah Llc | Method of treating severe forms of pulmonary hypertension |
CN115998955A (zh) * | 2022-12-09 | 2023-04-25 | 首都医科大学附属北京安贞医院 | 一种静脉桥的醛铬复合交联方法 |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3791988A (en) * | 1972-03-23 | 1974-02-12 | Hoffmann La Roche | Diagnostic test for glucose |
PL105793B1 (pl) | 1977-11-24 | 1979-10-31 | Sposob otrzymywania soli kwasow dwukarboksylowych i poliamin | |
IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4323558A (en) * | 1979-09-10 | 1982-04-06 | Nelson Research & Development Co. | Topical trien containing pharmaceutical compositions and methods of use |
US4371374A (en) | 1980-11-17 | 1983-02-01 | The Rockefeller University | Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine |
JPS57144215A (en) * | 1981-03-02 | 1982-09-06 | Nippon Nousan Kogyo Kk | Composition for improving lipometabolism |
DE3217071A1 (de) | 1982-05-06 | 1983-11-10 | Rüdiger Dr. 6365 Rosbach Gröning | Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe |
US4665192A (en) | 1984-03-19 | 1987-05-12 | The Rockefeller University | 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole |
US4758583A (en) * | 1984-03-19 | 1988-07-19 | The Rockefeller University | Method and agents for inhibiting protein aging |
US5852009A (en) * | 1984-03-19 | 1998-12-22 | The Rockefeller University | Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon |
EP0302065B1 (en) | 1986-03-21 | 1994-08-10 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
CH667590A5 (it) | 1986-07-24 | 1988-10-31 | Inpharzam Int Sa | Composizione farmaceutica effervescente idrosolubile contenente n-acetil-cisteina. . |
CH666814A5 (it) | 1986-07-24 | 1988-08-31 | Inpharzam Int Sa | Composizione farmaceutica idrosolubile contenente n-acetil-cisteina. |
US4866090A (en) * | 1988-01-07 | 1989-09-12 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
EP0331014A3 (de) | 1988-03-02 | 1991-10-23 | THERA - Patent Verwaltungs-GmbH | Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe |
JPH01294631A (ja) * | 1988-05-19 | 1989-11-28 | Sanwa Kagaku Kenkyusho Co Ltd | 糖尿性疾患治療予防剤及び飲食、し好物 |
US5077313A (en) * | 1988-11-25 | 1991-12-31 | Gert Lubec | Process for inhibiting pathological collagen cross-linking in diabetes patients |
CA2026686A1 (en) | 1989-10-30 | 1991-05-01 | Werner Tschollar | Method for preventing onset of type ii diabetes employing an ace inhibitor |
US5447728A (en) | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
EP0615458B1 (en) * | 1991-12-06 | 1997-08-06 | North Shore University Hospital Research Corporation | Method of reducing medical device related infections |
US5246970A (en) * | 1991-12-16 | 1993-09-21 | Washington University | Method of inhibiting nitric oxide formation |
JP3157622B2 (ja) | 1992-06-05 | 2001-04-16 | 株式会社ミツカングループ本社 | フルクトシルアミンデグリカーゼ、その製造法及び該酵素を用いたアマドリ化合物の定量方法 |
JPH06298738A (ja) * | 1993-04-15 | 1994-10-25 | Yamanouchi Pharmaceut Co Ltd | 5−アミノピラゾール誘導体 |
JPH07118148A (ja) | 1993-10-26 | 1995-05-09 | Tsumura & Co | 肝癌予防剤 |
US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
WO1995017900A1 (en) | 1993-12-30 | 1995-07-06 | Arcturus Pharmaceutical Corporation | Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways |
US5854271A (en) * | 1994-05-02 | 1998-12-29 | Cytos Pharmaceuticals, L.L.C. | Effective method for the amelioration and prevention of tissue and cellular damage |
WO1996012483A1 (en) | 1994-10-25 | 1996-05-02 | Washington University | Method of inhibiting nitric oxide formation |
AU716005B2 (en) * | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
JP3988838B2 (ja) * | 1996-05-29 | 2007-10-10 | 日本製粉株式会社 | 化粧料 |
US5906996A (en) * | 1996-08-21 | 1999-05-25 | Murphy; Michael A. | Tetramine treatment of neurological disorders |
CA2284170C (en) | 1997-03-11 | 2008-12-02 | The General Hospital Corporation | Identification of agents for use in the treatment of alzheimer's disease |
JPH10324629A (ja) * | 1997-03-28 | 1998-12-08 | Otsuka Pharmaceut Co Ltd | Age生成阻害組成物 |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US6576672B1 (en) * | 1998-08-21 | 2003-06-10 | Michael A. Murphy | Polyamine treatment of neurological disorders |
US20030013772A1 (en) * | 2000-02-23 | 2003-01-16 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
US20050085555A1 (en) * | 1997-08-21 | 2005-04-21 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
US5980914A (en) * | 1997-08-22 | 1999-11-09 | P.N. Gerolymatos S.A. | Clioquinol for the treatment of Parkinson's disease |
US6821954B2 (en) * | 1997-09-18 | 2004-11-23 | Auckland Uniservices Limited | Compounds and uses thereof in treating bone disorders |
US5972985A (en) * | 1997-11-03 | 1999-10-26 | Cytos Pharmaceuticals, Llc | Histidine containing nutriceutical compositions |
WO1999039712A1 (en) | 1998-02-04 | 1999-08-12 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
US6147070A (en) * | 1998-06-05 | 2000-11-14 | Facchini; Francesco | Methods and compositions for controlling iron stores to treat and cure disease states |
EP1234585A3 (en) | 1998-09-04 | 2004-01-21 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
WO2000018392A1 (en) * | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
AU772616B2 (en) * | 1998-09-25 | 2004-05-06 | Protemix Corporation Limited | Fructosamine oxidase assay: methods and materials |
JP2000204037A (ja) | 1999-01-12 | 2000-07-25 | Tsumura & Co | 筋萎縮性側索硬化症治療薬 |
US6309380B1 (en) * | 1999-01-27 | 2001-10-30 | Marian L. Larson | Drug delivery via conformal film |
US20030166561A1 (en) * | 1999-06-18 | 2003-09-04 | Cooper Garth J. S. | Peptide |
US20030050434A1 (en) * | 1999-06-18 | 2003-03-13 | Cooper Garth J.S. | Peptide |
AU759203B2 (en) | 1999-06-18 | 2003-04-10 | Protemix Discovery Limited | Peptide having preptin functionality |
WO2001085892A1 (en) * | 2000-05-11 | 2001-11-15 | The Procter & Gamble Company | Highly concentrated fabric softener compositions and articles containing such compositions |
US7754765B2 (en) * | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
DE60132494T2 (de) * | 2000-12-01 | 2008-12-24 | Radical Vision Therapeutics Inc. | Kupferchelatbildner zur behandlung von augenentzündungen |
NZ528509A (en) | 2001-03-30 | 2005-09-30 | Protemix Discovery Ltd | Phosphoprotein target for insulin and its antagonists |
WO2003002732A1 (en) | 2001-06-27 | 2003-01-09 | Biovitrum Ab | Citrate lyase poly peptides |
WO2003007686A2 (en) * | 2001-07-19 | 2003-01-30 | Dmi Biosciences, Inc. | Use of copper chelators to inhibit the inactivation of protein c |
US20040038861A1 (en) * | 2001-11-26 | 2004-02-26 | Cooper Garth J. S. | Methods and compositions for normalizing lipid levels in mammalian tissues |
AU2002356469A1 (en) | 2001-11-26 | 2003-06-10 | Protemix Corp Ltd | Methods of compositions for normalizing lipid levels in mammalian tissues |
AU2003207441A1 (en) | 2002-01-03 | 2003-07-24 | Duke University | Methods of modulating localization and physiological function of ip3 receptors |
CN1886423A (zh) * | 2002-01-18 | 2006-12-27 | 普罗特米克斯公司 | 脂联素的糖基同工型及其用途 |
WO2003062404A1 (en) * | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
EP1565172A2 (en) | 2002-01-29 | 2005-08-24 | Protemix Corporation Limited | Suppression of cytotoxic protein conformers |
EP1487874A4 (en) | 2002-03-01 | 2007-08-29 | Protemix Discovery Ltd | FALP PROTEINS |
WO2003075910A1 (en) * | 2002-03-08 | 2003-09-18 | Protemix Corporation Limited | Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure |
AU2003225442B2 (en) * | 2002-03-08 | 2010-02-04 | Philera New Zealand Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
CA2480987C (en) | 2002-04-03 | 2011-06-14 | Puleva Biotech, S.A. | Natural products and derivatives thereof for protection against neurodegenerative diseases |
WO2003093311A1 (en) | 2002-04-29 | 2003-11-13 | Protemix Corporation Limited | Proteins with deglycating activities and methods of using same |
CA2490541A1 (en) | 2002-05-24 | 2003-12-04 | The Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
JP2003343552A (ja) * | 2002-05-27 | 2003-12-03 | Koyo Seiko Co Ltd | 円錐ころ軸受 |
GEP20074270B (en) * | 2002-07-23 | 2007-12-25 | Univ Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
US7189865B2 (en) * | 2002-07-23 | 2007-03-13 | Attenuon, Llc | Thiomolybdate analogues and uses thereof |
US20040142393A1 (en) * | 2002-08-01 | 2004-07-22 | Cooper Garth James Smith | Methods of use of compounds with preptin function |
AU2003281842A1 (en) | 2002-08-01 | 2004-02-23 | Auckland Uniservices Limited | Preptin methods of use |
JP2006500341A (ja) | 2002-08-01 | 2006-01-05 | プロテミックス コーポレイション リミティド | プレプチン機能を有する化合物の使用方法 |
CA3011023A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Composition comprising triethylenetramine salts for treating tissue damage |
AU2003214725A1 (en) | 2002-08-20 | 2004-03-11 | Protemix Corporation Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
WO2004056861A2 (en) | 2002-12-23 | 2004-07-08 | Protemix Corporation Limited | Glycoisoforms of adiponectin and uses thereof |
US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US20070185072A1 (en) | 2003-03-21 | 2007-08-09 | Christophe Boldron | Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications |
CN1791408A (zh) | 2003-04-03 | 2006-06-21 | 普拉纳生物技术有限公司 | 神经系统疾病的治疗 |
KR20060015588A (ko) * | 2003-05-07 | 2006-02-17 | 디엠아이 바이오사이언시스, 인크 | 구강 케어 방법 및 제품 |
US7176239B2 (en) * | 2003-07-11 | 2007-02-13 | Suming Wang | Methods and compositions for treatment of Ataxia-telangeictasia |
CN1898260A (zh) | 2003-10-28 | 2007-01-17 | 普罗特米克斯发现有限公司 | 具有抗肥胖活性的肽及其它相关应用 |
EP1694317A4 (en) | 2003-12-19 | 2010-05-12 | Protemix Corp Ltd | COPPER ANTAGONIST COMPOUNDS |
CA2875095C (en) | 2004-07-19 | 2019-09-03 | Philera New Zealand Limited | Synthesis of triethylenetetramines |
WO2006068516A1 (en) | 2004-12-20 | 2006-06-29 | Protemix Corporation Limited | Implantable medical devices coated with or containing copper chelating compounds |
-
2003
- 2003-03-10 AU AU2003225442A patent/AU2003225442B2/en not_active Ceased
- 2003-03-10 EP EP03744567A patent/EP1487431B1/en not_active Expired - Lifetime
- 2003-03-10 DK DK03744567.3T patent/DK1487431T3/da active
- 2003-03-10 EP EP11187394.9A patent/EP2500018B1/en not_active Expired - Lifetime
- 2003-03-10 DK DK11187394.9T patent/DK2500018T3/en active
- 2003-03-10 CA CA2478997A patent/CA2478997C/en not_active Expired - Fee Related
- 2003-03-10 WO PCT/NZ2003/000042 patent/WO2003077901A1/en active Application Filing
- 2003-03-10 CN CNA038101513A patent/CN1649577A/zh active Pending
- 2003-03-10 ES ES03744567T patent/ES2386782T3/es not_active Expired - Lifetime
- 2003-03-10 JP JP2003575954A patent/JP4860906B2/ja not_active Expired - Fee Related
- 2003-03-10 AT AT03744567T patent/ATE555782T1/de active
- 2003-03-12 US US10/388,213 patent/US6951890B2/en not_active Expired - Lifetime
-
2005
- 2005-05-28 HK HK05104473.3A patent/HK1071313A1/xx not_active IP Right Cessation
- 2005-09-07 US US11/221,298 patent/US8034799B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 US US13/037,223 patent/US8563538B2/en not_active Expired - Fee Related
-
2013
- 2013-09-18 US US14/029,984 patent/US8987244B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2005533003A (ja) | 2005-11-04 |
US8563538B2 (en) | 2013-10-22 |
EP2500018A1 (en) | 2012-09-19 |
EP2500018B1 (en) | 2017-07-19 |
US8987244B2 (en) | 2015-03-24 |
US6951890B2 (en) | 2005-10-04 |
CN1649577A (zh) | 2005-08-03 |
CA2478997A1 (en) | 2003-09-25 |
WO2003077901A1 (en) | 2003-09-25 |
US20140113969A1 (en) | 2014-04-24 |
JP4860906B2 (ja) | 2012-01-25 |
US20060009534A1 (en) | 2006-01-12 |
ES2386782T3 (es) | 2012-08-30 |
AU2003225442B2 (en) | 2010-02-04 |
US8034799B2 (en) | 2011-10-11 |
ATE555782T1 (de) | 2012-05-15 |
EP1487431A4 (en) | 2006-10-25 |
AU2003225442A1 (en) | 2003-09-29 |
CA2478997C (en) | 2013-12-17 |
DK2500018T3 (en) | 2017-10-02 |
US20110212188A1 (en) | 2011-09-01 |
US20030203973A1 (en) | 2003-10-30 |
EP1487431A1 (en) | 2004-12-22 |
DK1487431T3 (da) | 2012-08-20 |
EP1487431B1 (en) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1071313A1 (en) | Preventing and/or treating cardiovascular disease and/or associated heart failure | |
CA2400801A1 (en) | Treatment of congestive heart failure by pretreated autologous blood | |
WO2005030291A3 (en) | Method and apparatus for treatment of thrombosed hemodialysis access grafts | |
ATE355852T1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
ATE370765T1 (de) | Zugangsleitung zur linken herrzkammer zur stimulierung bei herzversagen | |
EP1588736A3 (en) | Microperfusive electrical stimulation | |
WO2003026480A3 (en) | Methods and apparatus employing ionizing radiation for treatment of cardiac arrhythmia | |
DE69633195D1 (de) | Injektierbare oder implantierbare biomaterialien zum füllen oder abdecken von hohlräumen und lumen eines körpers | |
CO5611156A2 (es) | Metodos de tratamiento de enfermedad vascular | |
PT955880E (pt) | Metodo e aparelho para tratamento de arritmias cardiacas sem alvo discreto | |
BR0212252A (pt) | Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero | |
WO2002000210A3 (en) | Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease | |
WO2001032088A3 (en) | Method and apparatus for demand injury in stimulating angiogenesis | |
DE60335202D1 (en) | Chaperonin-10-immunosuppression | |
WO2002071955A3 (en) | Method and apparatus for treatment of atrial fibrillation | |
WO2000006185A3 (en) | Methods of using lanreotide, a somatostatin analogue | |
WO2003028524A3 (en) | Preparation of working fluid for use in cryotherapies | |
PL335046A1 (en) | Method of and agent for treating arteriosclerosis and vascular lesions by preventing proliferation of smooth muscle vascular fibres | |
PL354961A1 (en) | Prevention and treatment of diseases associated with blood coagulation | |
AU2003283227A8 (en) | Method and means for the treatment of vascular and cardiac diseases | |
AU6648200A (en) | Method and composition for preventing or treating adverse physiological effects associated with cardiac disease | |
WO2006007710A3 (en) | Acute inflammatory condition treatment | |
WO2002062204A3 (en) | Methods for diagnosing and treating heart disease | |
WO2002085376A3 (en) | A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress | |
WO2004037120A3 (en) | Implantable medical devices using zinc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210310 |